Navigation Links
Quest Diagnostics Reports Third Quarter 2010 Financial Results; Updates Guidance for 2010
Date:10/20/2010

d administrative expenses and offset the amount of investment gains and losses recorded in other income (expense), net.

For the three and nine months ended September 30, 2009, other income (expense), net includes gains of $3.8 million and $6.4 million, respectively, associated with investments held in trusts pursuant to our supplemental deferred compensation plans.  Additionally, for the nine months ended September 30, 2009, other income (expense), net includes a charge of $7.0 million associated with the write-down of an investment and charges of $7.6 million associated with the early extinguishment of debt.  

4) For the three months ended September 30, 2010, the Company repurchased 7.0 million shares of its common stock at an average price of $46.64 per share for $324 million.  For the nine months ended September 30, 2010, the Company repurchased 14.7 million shares of its common stock at an average price of $51.04 per share for $750 million.

For the three and nine months ended September 30, 2010, the Company reissued 0.1 million shares and 1.7 million shares, respectively, for employee benefit plans.  At September 30, 2010, our share repurchase authorization was fully utilized.  In October 2010, our Board of Directors authorized $250 million of additional share repurchases.

5) For the nine months ended September 30, 2009, cash flows from operating activities includes payments primarily made in the second quarter of 2009 totaling $314 million in connection with the NID settlement, $264 million net of an associated reduction in estimated tax payments.


'/>"/>
SOURCE Quest Diagnostics Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Quest Diagnostics Introduces ClariSure(TM) Test for Identifying Chromosome Abnormalities Associated With 85 Developmental Disorders in Children
2. VioQuest Pharmaceuticals Completes Enrollment of Phase I Trial of Lenocta(TM)
3. Two Point of Care Tests From Quest Diagnostics Receive FDA 510(k) Clearance
4. Video: Quest Diagnostics Health Trends(TM) Report Shows Significant Gap in Care for Patients With Chronic Kidney Disease
5. VioQuest Pharmaceuticals Announces Dosing of First Patient in Phase IIa Solid Tumor Study for Lenocta(TM), a Novel Protein Tyrosine Phosphatase Inhibitor
6. Centocor and Janssen-Cilag Submit Applications Requesting Approval of Ustekinumab in the U.S. and Europe for Treatment of Moderate to Severe Plaque Psoriasis
7. U.S. Patent Office Rejects Key HIV/AIDS Drug Patents at PUBPAT Request: Government Finds Prior Art Submitted By PUBPAT Invalidates All of Gilead Sciences Claims
8. Portrait(R) Plasma - A New Non-Surgical Option for one of the Most Requested Aesthetic Treatment - Aging Eyes
9. CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema
10. BRAVE-3 Questions Value of Abciximab in PCI for Heart Attack
11. ImQuest Publishes Results of Important Structure Activity Relationship Program on Dual Acting Pyrimidinediones
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... , October 17, 2014 Investor-Edge ... Inc. (NASDAQ: ARNA ), NPS Pharmaceuticals Inc. ... XOMA ), Momenta Pharmaceuticals Inc. (NASDAQ: ... Free research on these five companies can be accessed ... on Thursday, October 16, 2014, ended on a mixed ...
(Date:10/17/2014)... Oct. 17, 2014  UBM Medica US announces that ... endocrinologists and other clinicians who treat patients with ... effective use of insulin .  ... insulin replacement therapy – daily injections of one ... decline in the function of pancreatic beta cells. Insulin ...
(Date:10/17/2014)... Oct. 17, 2014  China Biologic Products, Inc. ... leading fully integrated plasma-based biopharmaceutical company in ... Company has received approval from the China Food ... of human prothrombin complex concentrate ("PCC") at its ... new coagulation factor production facility for Good Manufacturing ...
Breaking Medicine Technology:Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 2Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 3Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 4Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 5Endocrinology Network Features Special Coverage on Effective Use of Insulin 2Endocrinology Network Features Special Coverage on Effective Use of Insulin 3China Biologic Receives Approval for Commercial Manufacturing of Human Prothrombin Complex Concentrate at Shandong Taibang Facility 2China Biologic Receives Approval for Commercial Manufacturing of Human Prothrombin Complex Concentrate at Shandong Taibang Facility 3
... DIEGO, Nov. 11, 2010 Althea Technologies, Inc., a ... biopharmaceutical and parenteral products, announced today that Rick ...  Mr. Hancock brings twenty-seven years of industry experience and ... company into the future.  Mr. Hancock will lead the ...
... a meeting convened by the U.S. Food and Drug ... took the next step in advancing efforts toward the ... to ensure the safe and effective testing of artificial ... today,s meeting there was a strong consensus among leading ...
Cached Medicine Technology:Althea Technologies Announces Appointment of Rick Hancock as President 2JDRF Clinical Panel Recommends Next Steps for Artificial Pancreas Clinical Testing 2JDRF Clinical Panel Recommends Next Steps for Artificial Pancreas Clinical Testing 3JDRF Clinical Panel Recommends Next Steps for Artificial Pancreas Clinical Testing 4
(Date:10/20/2014)... 2014 Based on a proprietary ... imaging assays capable of determining DNA sequence, location ... these three dimensions of high-resolution data, dGH assays ... widest range of disease-causing genetic rearrangements, including chromosomal ... genomic tools, including today’s advanced sequencing technologies. , ...
(Date:10/20/2014)... It’s hard to imagine what it’s like to live ... the world, it’s a reality. And while new shoes are ... to walk barefoot on rocky terrain or sewage-lined streets just ... friends. , Buckner International's Shoes for Orphan Souls ... October to encourage support for Air1 and while also providing ...
(Date:10/19/2014)... 2014 Hastings and Hastings, a Phoenix ... service throughout the greater Phoenix area and across Arizona ... regard to catastrophic automobile accidents. Statistics have indicated a ... throughout Arizona. As such, Hastings and Hastings has seen ... for those who have been injured through no fault ...
(Date:10/19/2014)... 20, 2014 This report provides ... Seizure, complete with comparative analysis at various stages, ... (MoA), route of administration (RoA) and molecule type, ... press releases. It also reviews key players involved ... special features on late-stage and discontinued projects. , ...
(Date:10/19/2014)... a professional company of women’s dresses and related accessories, ... dresses . All the company’s old and new client ... up to 66 percent off. , SweetDressy.com is ... Its dress specialists are striving to make more trendy ... world. All the company’s items are unique, graceful and ...
Breaking Medicine News(10 mins):Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 2Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4Health News:Promotion For Beautiful Long Evening Dresses Launched By SweetDressy.com 2
... brain injury rehabilitation clinics and hospitals in the United States as ... currently living with the condition. Researchers believe that the quality and ... victim,s overall outcome. , ... Denver, CO (PRWEB) August ...
... (NASDAQ: QLTI;,TSX: QLT) announced today that QLT USA, ... license agreement with Reckitt Benckiser,Pharmaceuticals Inc. for its ... being retained by QLT USA and its,prior licensees. ... related asset,purchase agreement, QLT USA received an aggregate ...
... Aug. 25 Susan G. Komen for the ... and its sister organization,the Susan G. Komen for ... spread their message about breast self awareness and ... for the uninsured and,underinsured., (Logo: http://www.newscom.com/cgi-bin/prnh/20070122/NYM084LOGO ...
... 25 /Xinhua-PRNewswire-FirstCall/ -- Mindray,Medical International Limited (NYSE: ... medical devices in China, today released select historical,financial ... As announced in May, 2008, Mindray changed ... Chinese Renminbi effective April 1, 2008.,Accordingly, Mindray has ...
... CHESTER, Ohio, Aug. 25 AtriCure, Inc.,(Nasdaq: ATRC ... cardiac surgical,ablation systems, today announced that it will present ... Thomas Weisel Partners Healthcare Conference at the Four Seasons,Hotel ... Drachman,President and Chief Executive Officer, is scheduled to present ...
... study suggests cautions fail to alert docs to effectiveness ... -- Safety warnings slowed the use of antipsychotic drugs ... the drugs in the elderly increased, a finding which ... patients, Canadian researchers say. , Between late 2002 ...
Cached Medicine News:Health News:LegalView Highlights Top Brain Injury Rehabilitation Hospitals in the United States - 5.3 Million Americans Suffer from TBI 2Health News:LegalView Highlights Top Brain Injury Rehabilitation Hospitals in the United States - 5.3 Million Americans Suffer from TBI 3Health News:LegalView Highlights Top Brain Injury Rehabilitation Hospitals in the United States - 5.3 Million Americans Suffer from TBI 4Health News:QLT announces agreement to exclusively license the Atrigel(R) Technology to Reckitt Benckiser Pharmaceuticals Inc. 2Health News:QLT announces agreement to exclusively license the Atrigel(R) Technology to Reckitt Benckiser Pharmaceuticals Inc. 3Health News:Komen Travels to Democratic Convention in Denver to Raise Awareness of Breast Cancer Issues 2Health News:Mindray Releases Historical Financial Results Converted into US Dollar Terms 2Health News:AtriCure to Participate at the Thomas Weisel Partners Healthcare Conference and the UBS Global Life Sciences Conference in September 2Health News:Antipsychotic Drug Use Up in Elderly Despite Warnings 2
... to 350 Liters of pure water, Complete, ... of Purified Water,Millipores compact S.D.S. Storage and ... to 350 liters of purified water produced ... maintain consistent purity of stored water, provide ...
... a range of Milli-Q ultrapure water ... quality requirements. Each of the five ... specifically target contaminants detrimental to particular ... and ICP-MS. The systems incorporate a ...
... a range of Milli-Q ultrapure water ... quality requirements. Each of the five ... specifically target contaminants detrimental to particular ... and ICP-MS. The systems incorporate a ...
... Millipore has developed a range ... to match specific water quality requirements. ... systems is designed to specifically target ... as HPLC, molecular biology and ICP-MS. ...
Medicine Products: